<DOC>
	<DOCNO>NCT02133001</DOCNO>
	<brief_summary>The purpose study evaluate efficacy intranasal esketamine 84 milligram ( mg ) compare intranasal placebo along standard care treatment , reduce symptom major depressive disorder ( MDD ) ( affective disorder manifest either dysphoric mood loss interest pleasure usual activity , mood disturbance prominent relatively persistent ) , include risk suicide assess Investigator , participant assess imminent risk suicide .</brief_summary>
	<brief_title>A Double-blind Study Assess Efficacy Safety Intranasal Esketamine Rapid Reduction Symptoms Major Depressive Disorder , Including Suicidal Ideation , Participants Who Are Assessed Imminent Risk Suicide</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither physician participant know assign study treatment ) , placebo-controlled ( participant randomly assign test treatment identical-appearing treatment contain test drug ) , multicenter ( one hospital medical school team work medical research study ) , study esketamine participant major depressive disorder ( MDD ) participant assess imminent risk suicide , measure change Baseline Montgomery-Asberg Depression Rating Scale ( MADRS ) total score 4 hour postdose Day 1 . The duration study approximately 81 day per participant . The study consist 3 part : Screening ( , 1 day study commences Day 1 ) double-blind Treatment ( Day 1-25 ) Follow-up ( Day 26 Day 81 ) . All eligible participant provide standard care treatment randomly assign either esketmaine placebo treatment . Esketamine/placebo administer intranasal route ( delivery medication nasal mucosa ) two time per week 4 week . Efficacy participant primarily evaluate MADRS . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<criteria>Participants must meet Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) diagnostic criterion major depressive disorder Participants must current suicidal ideation intent In Investigator 's opinion , participant must need acute psychiatric hospitalization due imminent risk suicide Participant Montgomery Asberg Depression Rating Scale ( MADRS ) total score great equal ( &gt; = ) 22 predose Day 1 As part standard care treatment , participant agrees hospitalize voluntarily recommended period 5 day randomization ( , Day 5 ) , take prescribe noninvestigational antidepressant therapy ( y ) least duration doubleblind treatment phase ( Day 25 ) Participant current clinical diagnosis bipolar related disorder , intellectual disability , cluster b personality disorder ( example , borderline personality disorder , antisocial personality disorder , histrionic personality disorder , narcissistic personality disorder ) Participant meet DSMIV criterion borderline personality disorder , base clinical interview Participant current prior diagnosis psychotic disorder , major depressive disorder ( MDD ) psychosis , obsessive compulsive disorder Participant history current sign symptom liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , rheumatologic , metabolic disturbance Participant uncontrolled hypertension ( systolic blood pressure great [ &gt; ] 160 millimeter mercury [ mmHg ] diastolic blood pressure &gt; 90 mmHg ) despite diet , exercise stable dose allow antihypertensive treatment Screening ; past history hypertensive crisis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Esketamine</keyword>
	<keyword>Intranasal esketamine</keyword>
	<keyword>Placebo</keyword>
</DOC>